British Thyroid Association Survey of Graves' Disease Management in the UK
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15266 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Michael Atkinson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Swansea Bay University Health Board, Swansea, UK. Hauptthemen laut MEDLINE: Graves Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recent years have seen changes and uncertainties in evidence and guideline recommendations in Graves' disease treatment. To understand the impact of these developments on current practice, we undertook a survey of Graves' disease management in the United Kingdom and compared this to other national and international surveys.
Method
Members of the British Thyroid Association, the UK Society for Endocrinology and regional endocrinology networks, were invited by e‐mail to complete a 15‐min online survey (October 2022 to March 2023).
Results
Out of 158 eligible respondents, 99% were endocrinologists. For a 40‐year‐old female with a first presentation of Graves' hyperthyroidism, TSH‐receptor antibodies (TRAb) were requested at diagnosis and at follow‐up by 95% and 76%, respectively. Isotope scans and ultrasound were rarely requested (< 5%). Majority (95%) would treat with antithyroid drugs (ATD), predominantly Carbimazole (CMZ), while radioactive iodine (RAI) was preferred for recurrent disease (81%). Common reasons for avoiding RAI were thyroid eye disease, pregnancy intention, or contact with young children whereas biochemical severity, goitre, or male sex did not influence decision to use RAI. Propylthiouracil (PTU) was preferred in preconception and early pregnancy, but after the first‐trimester, 50% would continue PTU while 50% switch back to CMZ.
Conclusions
The survey confirms a growing application of TRAbs, both for diagnostic and prognostic purposes. ATDs remain the preferred first‐line therapy for Graves' disease, which is consistent with global trends but contrary to National Institute of Health and Care Excellence (NICE) guidance. Further studies are required to explore the clinical and pragmatic determinants of current treatment approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Swansea Bay University Health Board, Swansea, UK.
- Aneurin Bevan University Health Board, Newport, UK.
- Kingston Hospital NHS Foundation Trust, London, UK.
- Endocrinology, Aberdeen Royal Infirmary, Aberdeen, UK.
- Royal Devon & Exeter Hospital, University of Exeter Medical School, Exeter, UK.
- Cwm Taf Morgannwg Health Board, Merthyr Tydfil, UK.
ORCID-Profile: Koteshwara Muralidhara, Bijay Vaidya, Onyebuchi E Okosieme
Zitieren
APA
Atkinson, M., Agrawal, M., Muralidhara, K., Abraham, P., Vaidya, B., & Okosieme, O. E. (2025). British Thyroid Association Survey of Graves' Disease Management in the UK. Clinical Endocrinology. https://doi.org/10.1111/cen.15266
Vancouver
Atkinson M, Agrawal M, Muralidhara K, Abraham P, Vaidya B, Okosieme OE. British Thyroid Association Survey of Graves' Disease Management in the UK. Clinical Endocrinology. 2025. doi:10.1111/cen.15266
BibTeX
@article{Atkinson2025,
author = {Atkinson, Michael and Agrawal, Medha and Muralidhara, Koteshwara and Abraham, Prakash and Vaidya, Bijay and Okosieme, Onyebuchi E},
title = {British Thyroid Association Survey of Graves' Disease Management in the UK},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15266}
}
EUVIMED